Non-invasive MRI Screening for Sarcopenia, Portal Hypertension, and Liver Cancer in Adults with Advanced Liver Disease
Led by Linkoeping University · Updated on 2023-08-24
150
Participants Needed
3
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Patients with established liver cirrhosis or end-stage liver disease face a high risk of developing liver cancer, portal hypertension, and muscle loss called sarcopenia, which can lead to serious health problems and death. This research aims to evaluate these conditions using a single short magnetic resonance MR scan. The goal is to improve early detection of liver cancer and better predict liver complications to help guide treatment decisions.
The study involves 150 patients who will undergo four visits every six months over about two years, with an additional visit for some patients. Each visit includes a detailed clinical assessment, medical history review, FibroScan, MR examination, blood tests, muscle strength and mobility tests, quality of life questionnaires, and assessments for liver-related symptoms. The MR scan will capture body composition and liver measurements, including muscle volume, muscle fat, liver fat, spleen size, and liver stiffness. Specialized software will analyze these images to monitor sarcopenia and portal hypertension while liver cancer screening will be done using advanced MR techniques.
Participants will be actively involved throughout the study period, attending scheduled visits alongside their routine clinical appointments. Researchers will measure changes in body composition, muscle fat, liver function scores, muscle strength, liver cancer presence, and other liver complications at multiple timepoints. Quality of life and symptom assessments will also be collected. The study aims to provide comprehensive data on liver disease progression, muscle loss, and cancer detection, helping to improve patient care and outcomes over the two-year follow-up.
CONDITIONS
Brief Title
Relevance of Sarcopenia in Advanced Liver Disease
Research Team
M
Mattias Ekstedt, MD, PhD
M
Mikael Forsgren, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Established or probable liver cirrhosis based on clinical practice at the study hospital
Age 18 years or older
Provided written informed consent to participate
You will not qualify if you...
Contraindications for undergoing MRI
Diagnosis of primary sclerosing cholangitis (PSC)
Diagnosis of hepatocellular carcinoma (liver cancer)
Previous liver transplant
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Approximately 24 months
Participants undergo regular clinical assessments including clinical work-up, imaging, blood tests, muscle function and mobility assessments, and quality of life evaluations to monitor liver disease progression and related symptoms.
4 visits every 6 months (5 visits for some participants with LI-RADS 3), scheduled alongside routine clinical visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Evaluating 18F-FDGal PETCT and PETMRI for Diagnosis and Treatment Monitoring in Adults with Hepatocellular Carcinoma
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Using 3D Magnetic Resonance Elastography to Assess Cirrhosis, Advanced Chronic Liver Disease, and Portal Hypertension
A Prospective Multicenter Study to Develop a Non-Invasive Risk Stratification Method
Non-invasive 4D-Flow MRI to Assess Portal Hypertension and Predict Outcomes After TIPS in Cirrhosis
Phase 2 Study of 68Ga-PSMA-11 PET-Guided Radioligand Therapy with 177Lu-PSMA-617 in Adults with Metastatic Hepatocellular Carcinoma
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Evaluating Multimodal Ultrasound to Monitor Muscle Mass in Metabolic Syndrome, Type 2 Diabetes, and Obesity
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Open Label Study Evaluating BAY 3547926 Safety and Activity in Advanced Hepatocellular Carcinoma Patients
Comparing MRI, CT, and Two PET Scans 18F-FDGal and 18F-choline for Diagnosing Hepatocellular Carcinoma in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol.